Alan Wade1, Susan Downie. 1. CPS Research, 3 Todd Campus, West of Scotland Science Park, Glasgow, G20 0KA, Scotland. alangwade@fastmail.fm
Abstract
BACKGROUND: Clinical data show that poor quality, rather than quantity, of sleep corresponds negatively to measures of health, well-being and satisfaction with life. However, until now treatment of insomnia has primarily targeted quantity of sleep. PR (prolonged release)-melatonin offers a new treatment option in insomnia. OBJECTIVES: To provide an overview of PR-melatonin, the first melatonin receptor agonist to be granted marketing authorisation in Europe as monotherapy for the treatment of primary insomnia in patients aged > 55 years. METHODS: Review data published in peer review journals and the EMEA (European Medicines Agency) website. RESULTS/ CONCLUSION: PR-melatonin significantly improves morning alertness and quality of sleep compared with placebo. There are no safety concerns.
BACKGROUND: Clinical data show that poor quality, rather than quantity, of sleep corresponds negatively to measures of health, well-being and satisfaction with life. However, until now treatment of insomnia has primarily targeted quantity of sleep. PR (prolonged release)-melatonin offers a new treatment option in insomnia. OBJECTIVES: To provide an overview of PR-melatonin, the first melatonin receptor agonist to be granted marketing authorisation in Europe as monotherapy for the treatment of primary insomnia in patients aged > 55 years. METHODS: Review data published in peer review journals and the EMEA (European Medicines Agency) website. RESULTS/ CONCLUSION:PR-melatonin significantly improves morning alertness and quality of sleep compared with placebo. There are no safety concerns.
Authors: Andrew H Ford; Leon Flicker; Jurgen Passage; Bradley Wibrow; Matthew Anstey; Mark Edwards; Osvaldo P Almeida Journal: Trials Date: 2016-01-28 Impact factor: 2.279
Authors: Pawel P Posadzki; Ram Bajpai; Bhone Myint Kyaw; Nicola J Roberts; Amnon Brzezinski; George I Christopoulos; Ushashree Divakar; Shweta Bajpai; Michael Soljak; Gerard Dunleavy; Krister Jarbrink; Ei Ei Khaing Nang; Chee Kiong Soh; Josip Car Journal: BMC Med Date: 2018-02-05 Impact factor: 8.775